Company profilePharmaceutical#689 of 1,318 in Pakistan✓ No DRAP alerts

MAQ

Pharmaceutical company · 14 brands · 14 molecules

Ranked #7 of 24 companies in Drugs For Treatment Of Bone Diseases

14 registered products 14 pharmaceutical brands 14 distinct molecules 0 DRAP alerts

Company overview

14
registered products
14
pharmaceutical brands
14
distinct molecules
11
therapeutic classes
0
DRAP alerts

MAQ is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 14 product registrations across 14 distinct molecules. Its portfolio is concentrated in Drugs For Treatment Of Bone Diseases and Antiinflammatory And Antirheumatic Products. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Top molecules by brand count

Therapeutic classes

Drugs For Treatment Of Bone Diseases · 2Antiinflammatory And Antirheumatic Products · 2Pain Management · 2Muscle Relaxant · 2Blood Glucose Lowering Drugs, Excluding Insulin · 2Antivertigo Preparations · 1Cough And Cold Preparations · 1Antihistamines For Systemic Use · 1Antiepileptics · 1Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 1Antidepressants · 1

Conditions treated

Arthritis · 1Muscle Relaxant/Spasm · 1

Price band (DRAP official ceilings)

Registered products priced by source
DVAGO2 products · Rs 206.6 – Rs 376.8
Servaid2 products · Rs 255 – Rs 1,014.9
Median across source: Rs 634.95

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Get the full profile for MAQ

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.